Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced positive results from its Phase 3 VELOUR trial for ZALTRAP (aflibercept) in combination with FOLFIRI for the second-line treatment of metastatic colorectal cancer (mCRC). The trial met its primary endpoint, demonstrating an improvement in overall survival (OS) compared to FOLFIRI plus placebo. These findings, presented at the ESMO World Congress on Gastrointestinal Cancer, represent a significant milestone for Regeneron's lead product candidate and its potential in a key oncology indication. The data presented suggests ZALTRAP could offer a meaningful therapeutic benefit to patients with advanced colorectal cancer. This development is crucial for investors as it advances the commercial prospects of aflibercept and reinforces Regeneron's drug development pipeline. The company has furnished a presentation detailing these trial results, providing investors with direct insight into the scientific and clinical validation of ZALTRAP.
Key Highlights
- 1Regeneron's Phase 3 VELOUR trial for ZALTRAP (aflibercept) met its primary endpoint in metastatic colorectal cancer (mCRC).
- 2The trial demonstrated improved overall survival (OS) when ZALTRAP was combined with FOLFIRI chemotherapy compared to FOLFIRI plus placebo.
- 3The positive results were presented at the ESMO World Congress on Gastrointestinal Cancer.
- 4ZALTRAP is being evaluated in combination with FOLFIRI for the second-line treatment of mCRC.
- 5A presentation detailing the VELOUR trial results has been furnished as an exhibit to the 8-K filing.